LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:

• Induction ends on day 19

• Consolidation ends on day 38 or 42

• Maintenance may include up to 6 cycles

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Asparaginase; Cyclophosphamide; Daunorubicin; Methotrexate

Criteria

Inclusion Criteria:

• Non-Hodgkin's Lymphoma stages III, IV, IVA with

1. T cell lymphomas, any primary site irrespective of LDH level

2. large cell lymphomas, any primary site irrespective of LDH level

3. B cell lymphomas, any primary site with initial LDH of less than 500

Exclusion Criteria:

• B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement